Eupraxia Pharmaceuticals Management
Management criteria checks 3/4
Eupraxia Pharmaceuticals' CEO is James Helliwell, appointed in Jul 2012, has a tenure of 12.33 years. total yearly compensation is $517.30K, comprised of 70.2% salary and 29.8% bonuses, including company stock and options. directly owns 1.89% of the company’s shares, worth CA$3.10M. The average tenure of the management team and the board of directors is 2.8 years and 11.8 years respectively.
Key information
James Helliwell
Chief executive officer
US$517.3k
Total compensation
| CEO salary percentage | 70.2% |
| CEO tenure | 12.3yrs |
| CEO ownership | 1.9% |
| Management average tenure | 2.8yrs |
| Board average tenure | 11.8yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$27m |
| Mar 31 2024 | n/a | n/a | -US$30m |
| Dec 31 2023 | US$517k | US$363k | -US$28m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$20m |
| Dec 31 2022 | US$953k | US$325k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$1m | US$297k | -US$19m |
Compensation vs Market: James's total compensation ($USD517.30K) is above average for companies of similar size in the Canadian market ($USD170.32K).
Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.
CEO
James Helliwell (50 yo)
12.3yrs
Tenure
US$517,299
Compensation
Dr. James A. Helliwell, M.D., FRCPC serves as the Chief Executive Officer since July 2012 at Eupraxia Pharmaceuticals Inc. and served as its President until May 3, 2021. Dr. Helliwell serves as a Clinical...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 12.3yrs | US$517.30k | 1.89% CA$ 3.1m | |
| President & CFO | 3.5yrs | US$368.72k | 0.32% CA$ 525.7k | |
| Chief Scientific Officer & COO | 12.2yrs | US$368.72k | 0.13% CA$ 213.2k | |
| Chief Business Officer | 2yrs | US$343.12k | 0.076% CA$ 125.1k | |
| Chief Medical Officer | 1.5yrs | US$1.15m | 0.022% CA$ 36.8k | |
| Executive Vice President of Corporate Development | less than a year | no data | no data |
2.8yrs
Average Tenure
56.5yo
Average Age
Experienced Management: EPRX's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 12.3yrs | US$517.30k | 1.89% CA$ 3.1m | |
| Independent Chairman | 11.8yrs | US$42.23k | 0.024% CA$ 39.7k | |
| Independent Director | 3.7yrs | US$29.86k | 0.039% CA$ 64.1k | |
| Independent Director | 11.8yrs | US$23.56k | 0.96% CA$ 1.6m | |
| Director | no data | no data | 4.21% CA$ 6.9m | |
| Independent Director | 11.8yrs | US$29.86k | 3.4% CA$ 5.6m | |
| Independent Director | 11.8yrs | US$23.56k | 0.63% CA$ 1.0m |
11.8yrs
Average Tenure
57yo
Average Age
Experienced Board: EPRX's board of directors are seasoned and experienced ( 11.8 years average tenure).